487 related articles for article (PubMed ID: 28797106)
1. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y; Imamura M; Aikata H; Daijo K; Teraoka Y; Honda F; Nakamura Y; Hatooka M; Morio R; Morio K; Kan H; Fujino H; Kobayashi T; Masaki K; Ono A; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Hayes CN; Miki D; Ochi H; Chayama K
PLoS One; 2017; 12(8):e0182710. PubMed ID: 28797106
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
[TBL] [Abstract][Full Text] [Related]
3. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
4. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens.
Tayyab GUN; Rasool S; Nasir B; Rubi G; Abou-Samra AB; Butt AA
BMC Gastroenterol; 2020 Apr; 20(1):93. PubMed ID: 32252635
[TBL] [Abstract][Full Text] [Related]
6. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
7. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
8. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Roulot D; Thibault V; Laforest C; Fontaine H; Bronowicki JP; Asselah T; Bourlière M; Canva V; Leroy V; Loustaud-Ratti V; Ouzan D; Zoulim F; Schischmanoff O; Rousseau C; Renault A; Petrov-Sanchez V; Diallo A; Bellissant E; Serfaty L;
Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):302-309. PubMed ID: 29271782
[TBL] [Abstract][Full Text] [Related]
10. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Serti E; Park H; Keane M; O'Keefe AC; Rivera E; Liang TJ; Ghany M; Rehermann B
Gut; 2017 Apr; 66(4):724-735. PubMed ID: 26733671
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Yoshida K; Hai H; Tamori A; Teranishi Y; Kozuka R; Motoyama H; Kawamura E; Hagihara A; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28467359
[TBL] [Abstract][Full Text] [Related]
12. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Akuta N; Kobayashi M; Suzuki F; Sezaki H; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
Oncology; 2016; 91(6):341-347. PubMed ID: 27694754
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Nam HC; Lee HL; Yang H; Song MJ
Clin Mol Hepatol; 2016 Jun; 22(2):259-66. PubMed ID: 27377910
[TBL] [Abstract][Full Text] [Related]
14. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Fukui H; Inui Y; Hijioka T; Inada M; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1186-95. PubMed ID: 24321207
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
17. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Maruyama T; Tanabe Y; Satoh T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Hepatol; 2013 Mar; 58(3):495-501. PubMed ID: 23099187
[TBL] [Abstract][Full Text] [Related]
19. Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.
Lee SH; Jin YJ; Shin JY; Lee JW
Medicine (Baltimore); 2017 Jan; 96(1):e5321. PubMed ID: 28072684
[TBL] [Abstract][Full Text] [Related]
20. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
